Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PKM-02
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Bpifrance
Deal Size : $1.6 million
Deal Type : Financing
PK MED Receives €1.5M DeepTech Financing from Bpifrance for Cell-Homing Implant
Details : The funding will accelerate the company’s PKM-02, an innovative technology aiming to enhance bone marrow transplantation in several diseases with high unmet medical need such as hemoglobinopathies.
Product Name : PKM-02
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 24, 2024
Lead Product(s) : PKM-02
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Bpifrance
Deal Size : $1.6 million
Deal Type : Financing
Lead Product(s) : Colchicine,Ropivacaine Hydrochloride
Therapeutic Area : Rheumatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PK MED Gets FDA Clearance to Initiate Clinical Program for PKM-01 in Gout Flares
Details : PKM-01 (colchicine) is an intra-articular combination of a fast-acting anesthetic and a controlled-release form of a powerful anti-inflammatory agent (colchicine). Being evaluated for gout flares.
Product Name : PKM-01
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 26, 2024
Lead Product(s) : Colchicine,Ropivacaine Hydrochloride
Therapeutic Area : Rheumatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
